Targeted Therapy for Lung Cancer: 326 Real Stories

326 stories match lung cancer and targeted therapy. 150 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA ALK-positive lung adenocarcinoma: pathologic complete response to lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: EML4-ALK fusion; ALK-positive; Napsin A-positive; cytokeratin-positive; TTF-1-positive

He remained disease-free 10 months after surgery while continuing planned adjuvant lorlatinib after neoadjuvant lorlatinib produced partial radiographic response and pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer with acquired resistance to osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR L858R; acquired EGFR T790M; acquired EGFR L718Q

Metastatic Site: pleura, bone

After temporary disease control with sequential EGFR-targeted therapies, the right lung lesion enlarged again in June 2021; she was alive at the latest follow-up.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer treated after osimertinib resistance

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R, TP53 mutation; acquired EGFR T790M; acquired EGFR L718Q

Metastatic Site: lungs, bone

Dacomitinib produced brief stable disease, but the lung cancer progressed again by September 2021; she was alive at the latest follow-up.

PubMed Central
OutcomeSetback / Progression
Leah, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (spine, pelvis); malignant right pleural…

As of July 2024, Leah remained on daily Tagrisso with stable Stage IV EGFR-mutated lung cancer, no reported progression, healing/sclerotic bone metastases, and durable response for more than 4 years.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA ALK-rearranged NSCLC: pathologic complete response to neoadjuvant brigatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: ALK gene rearrangement; CEA 8.49 ng/mL

He remained disease-free during 13 months of follow-up after neoadjuvant brigatinib reduced Stage IIIA ALK-rearranged NSCLC and curative-intent surgery showed pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Near-complete response to osimertinib in Stage IV lung adenocarcinoma with rare EGFR mutations

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR S768I mutation, PD-L1 TPS 2%

Metastatic Site: pleura, bone, lymph nodes

After progression on vinorelbine and carboplatin, osimertinib produced a metabolic complete response by December 2023 and a near-complete radiologic response in March 2024. He remained on osimertinib with good tolerance and stable clinical condition.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

RET-fusion lung adenocarcinoma responding to pralsetinib and bevacizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KIF13A-RET fusion

Metastatic Site: pleura

He had 27 months of disease-free survival on pralsetinib before pleural and nodal recurrence. After bevacizumab was added, imaging showed reduction of the pleural lesion and mediastinal nodes and circulating tumor DNA became undetectable in December 2023.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

More than five years with EGFR-mutated lung cancer and untreated brain metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: brain, pleura

Zorifertinib produced partial responses in both brain and extracranial disease, with 3 years of progression-free survival and more than 4 years of intracranial control. By December 2023, she remained alive on aumolertinib with overall survival of more than 65 months, or 5+ years, from treatment start.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

MET-Positive Metastatic Lung Cancer That First Appeared as a Breast Mass

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; acquired MET and resistance mutations

Metastatic Site: breast, liver, right adrenal gland

Capmatinib produced a marked response across most disease sites at 3 months, but a right adrenal metastasis progressed by 6 months while other sites continued responding.

PubMed Central
OutcomeSetback / Progression
Daniel, who was diagnosed with Stage II Non-Small Cell Lung CancerLung Cancer

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

AACR
OutcomeCancer-Free / NED
Niko, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ALK Lung Adenocarcinoma: Niko's Patient Story

Patient Info: Niko, Female | Stage IV

Biomarkers: ALK mutation/rearrangement

Metastatic Site: Lymph nodes; Brain

As of May 2024, Niko’s Stage IV ALK-positive lung adenocarcinoma was controlled on ALK-targeted therapy, with no brain lesion seen on follow-up MRI/PET-CT and active disease described as dormant/stable.

YouTube (ZH search)
OutcomeResponding Well
Jeff, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research Foundation
OutcomeResponding Well